$695 | Single User
$3475 | Site License
$10425 | Global License

New Thinking in Patient Adherence
[Lowest Price Guaranteed: $695]

Published by FirstWord Pharma: 01 Mar 2012 | 8 | In Stock
Related Topics: Business , Compliance , Consumer , GlaxoSmithKline , Healthcare , Life , Packaging , Pricing

Introduction

Introduction


Patient non-adherence is estimated to represent 0 billion per year in avoidable medical expenses in the United States alone. Consumers’ motivations for non-compliance are complex; up to 80% of people are intentionally not taking their prescription drugs as directed.


There is no better time for pharma companies to reflect on their patient-adherence strategies. Not only is it more cost-effective to focus on retaining, rather than acquiring, customers, but it is also an ideal way of working with other stakeholders, as patient-centric policies are implemented in healthcare systems round the world. Moreover, digital innovations are creating new opportunities for stakeholders to join forces in a concerted effort to educate patients about why taking their medications is so essential to their health.


Scope


Report Overview

New Thinking in Patient Adherence goes far beyond presenting data on consumer behaviour. This comprehensive and insightful report reveals a shift towards a more holistic approach to the problem, and reviews a wealth of innovative tactics that are being used to address compliance and persistence issues worldwide. You’ll learn about new ways that leading pharmaceutical companies are collaborating with other healthcare stakeholders, including clinicians, pharmacists, payers, and health systems. This up-to-the-minute report also provides details on effective educational initiatives, and the very latest technological solutions, including smart pills and packaging, mobile applications, and remote monitoring.


Highlights


Key Report Features


  • Roundup of the latest intelligence on why consumers do not follow doctors' orders

  • Leading adherence trends – focus on clinical outcomes, and greater coordination among stakeholders (with insights from Novo Nordisk's DAWN study – showing that collaboration with stakeholders is key)

  • Detailed examination of pharma collaborations with pharmacists, physicians, payers, and health systems

  • Latest adherence strategies, solutions, and technological innovations

  • Puchase Reasons


    Key Benefits


  • How pioneering pharma companies, including GlaxoSmithKline and Merck, are reorganising to prioritise adherence initiatives

  • Practical strategies and tactics to address adherence issues

  • Up-to-the-minute view of the latest available solutions

  • Key Questions Answered


  • Why have so many adherence interventions failed?

  • How are new technologies being harnessed to improve adherence?

  • What economic factors are driving adherence-focused collaborations between pharma companies and insurers?

  • How are the critical roles in patient adherence played by primary care physicians and pharmacists changing?

  • Who Would Benefit From This Report?


    This report will be of value to senior pharma directors and managers with responsibilities in the following areas:

  • Market access

  • Patient adherence

  • Pricing and reimbursement

  • Key account and territory management

  • Marketing, brand and sales management

  • Consumer marketing solutions

  • Advertising and promotion

  • Business development

  • CRM and relationship marketing

  • Multi-channel marketing

  • Strategic brand planning solutions

  • Forecasting and marketing professionals

  • The report will also benefit providers of consultancy and technology services and solutions for patient education and adherence, relationship marketing and market research.


    Key quotes


    “It is a multi-dimensional problem. And one important aspect is how patients relate to their physicians and pharmacists. I believe there are more than 40,000 articles published on adherence and more than 90 percent of these have looked almost entirely at patient behaviour alone.”

    – Colleen A McHorney, Senior Director of US Outcomes Research, Merck.


    “There is not one single barrier to adherence. That is why it is so important to work collaboratively. For consumers to change their behaviour they need to be aware of the problem. That means they have to see messages all around them—at the doctor’s office, at work, at the pharmacy.”

    – Rebecca Burkholder, vice-president of Health Policy at NCL.


    “As integrated health networks start to introduce key performance indicators for what actually happens to the patients in their care and to become more accountable, pharma companies have more incentive to move towards collaboration.”

    – Thomas Forissier, Principal, Life Sciences Strategy, CapGemini Consulting.


    Expert Views


  • Colleen A McHorney, senior director of US Outcomes Research, Merck

  • Søren Skovlund, head of the DAWN programme, Novo Nordisk

  • Chris Preti, head of Patient Engagement group, GlaxoSmithKline

  • Oliver Johnston, European head of marketing at Plovia, GlaxoSmithKline

  • Francisco Abad, Seretide marketing manager, GlaxoSmithKline

  • Thomas Forissier, principal, Life Sciences Strategy, CapGemini Consulting

  • Vernon F Schabert, principal, Health Economics and Outcomes Research, IMS Consulting

  • Walter Berghahn, executive director, Healthcare Compliance Packaging Council

  • Dr Michael Ackermann, senior vice president, Global Commercial Solutions, Quintiles

  • Greg Muffler, CEO, CellepathicRx

  • Rebecca Burkholder, vice-president, Health Policy, National Consumers League

  • Carole North, director, 90TEN Healthcare
  • Table of Contents
    for New Thinking in Patient Adherence

    • 1.Executive summary

      2.Introduction

      2.1. Non-adherence has deep roots

      2.2. Narrow focus of research

      2.3. Effectiveness of adherence interventions

      2.4. Barriers to adherence

      2.5. Intentional and unintentional factors

      2.6. Various shades of grey

      2.7. A challenge for pharma

      3.Trends favouring medical adherence

      3.1. Focus on health outcomes

      3.2. Greater coordination among stakeholders

      3.3. Initiatives in Europe

      3.4. Script your Future in the US

      4.Pharma collaborations

      4.1. …with pharmacists

      4.2. GSK's Community Outreach Team

      4.3. Pharmacy innovation

      4.4. …with payers and healthcare systems

      4.5. Collaborating on patient pathways

      4.6. Collaboration via an intermediary

      4.7. Co-pays

      4.8. …with physicians

      4.9. Insights from DAWN

      5.Adherence solutions

      5.1. Making life simpler for the patient

      5.2. Packaging solutions

      5.3. Pill bottles

      5.4. Smart pills

      5.5. Medication management

      5.6. Drug delivery

      5.7. Reminders and education programmes

      5.8. Case study: Prolong

      6.Mobile health

      6.1. MyAsthma app

      6.2. Remote monitoring

      7. Restructuring to tackle adherence

      7.1. Organisation of adherence initiatives

      7.2. Central adherence efforts

      7.3. Exception rather than the rule

      7.4. Owning the adherence challenge

      7.5. Measuring adherence

      7.6. The way forward

      8.Acknowledgements

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    8 |

    Number of Pages

    62

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Design Thinking Market Research Report 2020 (Covid-19 Version)
    SummaryMarket Segment as follows:By Region Asia-Pacific North America Europe South Ameri...
    31 Jul 2020 by HeyReport USD $3,500 More Info
    Global Visual Thinking Software Market Research Report 2020 (Covid-19 Version)
    SummaryMarket Segment as follows:By Region Asia-Pacific North America Europe South Ameri...
    31 Jul 2020 by HeyReport USD $3,500 More Info
    Physician Views: How have recent data, study design events shaped doctors’ thinking on lead NASH agents
    ScopeBiotech is a notoriously volatile sector, and pure-play nonalcoholic steatohepatitis (NASH) dru...
    01 Jun 2015 by FirstWord Pharma USD $695 More Info
    Engaging KOLs: new thinking on thought leader development
    IntroductionKey opinion leaders (KOLs) play a vital role in the effective development and marketing ...
    01 Mar 2012 by FirstWord Pharma USD $595 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    New Thinking in Patient Adherence | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...